247 related articles for article (PubMed ID: 28448381)
1. Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics.
Abelson JS; Michelassi F; Mao J; Sedrakyan A; Yeo H
Ann Surg; 2018 Aug; 268(2):311-317. PubMed ID: 28448381
[TBL] [Abstract][Full Text] [Related]
2. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
[TBL] [Abstract][Full Text] [Related]
3. As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection.
Kin C; Kate Bundorf M
J Gastrointest Surg; 2017 Jul; 21(7):1159-1165. PubMed ID: 28484890
[TBL] [Abstract][Full Text] [Related]
4. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.
Kaplan GG; Lim A; Seow CH; Moran GW; Ghosh S; Leung Y; Debruyn J; Nguyen GC; Hubbard J; Panaccione R
World J Gastroenterol; 2015 Jan; 21(4):1251-60. PubMed ID: 25632199
[TBL] [Abstract][Full Text] [Related]
5. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis.
Andrew RE; Lauria A; Puleo FJ; Berg A; Stewart DB
J Surg Res; 2017 Nov; 219():18-24. PubMed ID: 29078879
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study.
Ward ST; Mytton J; Henderson L; Amin V; Tanner JR; Evison F; Radley S
Colorectal Dis; 2018 May; 20(5):416-423. PubMed ID: 29059479
[TBL] [Abstract][Full Text] [Related]
7. Prolonged preoperative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis.
Coakley BA; Telem D; Nguyen S; Dallas K; Divino CM
Surgery; 2013 Feb; 153(2):242-8. PubMed ID: 23062652
[TBL] [Abstract][Full Text] [Related]
8. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
Kurnool S; Nguyen NH; Proudfoot J; Dulai PS; Boland BS; Vande Casteele N; Evans E; Grunvald EL; Zarrinpar A; Sandborn WJ; Singh S
Aliment Pharmacol Ther; 2018 Jun; 47(11):1472-1479. PubMed ID: 29665045
[TBL] [Abstract][Full Text] [Related]
9. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.
Thorne K; Alrubaiy L; Akbari A; Samuel DG; Morrison-Rees S; Roberts SE
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):369-82. PubMed ID: 26825217
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and complications after colectomy in patients with ulcerative colitis.
Bregnbak D; Mortensen C; Bendtsen F
J Crohns Colitis; 2012 Apr; 6(3):281-6. PubMed ID: 22405163
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
13. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for Ulcerative Colitis With Delayed Emergency Colectomy Are Worse When Controlling for Preoperative Risk Factors.
Leeds IL; Sundel MH; Gabre-Kidan A; Safar B; Truta B; Efron JE; Fang SH
Dis Colon Rectum; 2019 May; 62(5):600-607. PubMed ID: 30451754
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
[TBL] [Abstract][Full Text] [Related]
16. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
17. An approach to acute severe ulcerative colitis.
Sedano R; Quera R; Simian D; Yarur AJ
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):943-955. PubMed ID: 31648574
[No Abstract] [Full Text] [Related]
18. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis.
Gu J; Stocchi L; Remzi F; Kiran RP
Colorectal Dis; 2013 Sep; 15(9):1123-9. PubMed ID: 23627886
[TBL] [Abstract][Full Text] [Related]
19. Surgical outcomes among inflammatory bowel disease patients undergoing colectomy : results from a national database.
Rahal MA; Karaoui WR; Mailhac A; Tamim H; Shaib Y
Acta Gastroenterol Belg; 2018; 81(3):387-392. PubMed ID: 30350526
[TBL] [Abstract][Full Text] [Related]
20. Ulcerative colitis-associated hospitalization costs: a population-based study.
Coward S; Heitman SJ; Clement F; Hubbard J; Proulx MC; Zimmer S; Panaccione R; Seow C; Leung Y; Datta I; Ghosh S; Myers RP; Swain M; Kaplan GG
Can J Gastroenterol Hepatol; 2015 Oct; 29(7):357-62. PubMed ID: 26079072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
